Stock listing

Dusseldorf:1HM Adaptive Biotechnologies Corporation Aktie

German listing (Dusseldorf) of Adaptive Biotechnologies Corporation · home listing NASDAQ:ADPT

Follow Adaptive Biotechnologies Corporation into a list and get an email when it puts out news.

Share price · DUS:1HM

€23.41 EUR -1.29 (-5.2%)

Close on Oct 30, 2026

Day range
€23.41 – €24.89 EUROct 30, 2026
Market cap
€3.63B EURAt the close on Oct 30, 2026 · price × 155.3M shares outstanding
Adaptive Biotechnologies Corporation logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ADPT · Home$26.64 USD-1.53 (-5.4%)4,256,397$27.36$27.97$26.17$28.17Close on Oct 30, 2026
Dusseldorf:1HM€23.41 EUR-1.29 (-5.2%)—€24.89€24.89€23.41€24.70Close on Oct 30, 2026
Frankfurt:1HM€23.28 EUR+0.75 (+3.3%)—€23.28€23.28€23.28€22.53Close on Oct 27, 2026
Munich:1HM€23.28 EUR+1.25 (+5.7%)—€23.28€23.28€23.28€22.03Close on Oct 27, 2026
Ticker
Dusseldorf:1HM
Asset type
Stock
Exchange
Dusseldorf
Currency
EUR

What changed lately

Calls

Upcoming

  • Adaptive Biotechnologies (NASDAQ:ADPT) Q3 2026 Earnings Call

    Wed, Nov 04, 2026 · 4:30 PM ET

    Register

Replays

  • Adaptive Biotechnologies (NASDAQ:ADPT) Q2 2026 Earnings Call

    Wed, Jul 29, 2026 · 4:30 PM ET

    Watch Transcript

  • Adaptive Biotechnologies (NASDAQ:ADPT) Q1 2026 Earnings Call

    Tue, May 05, 2026 · 4:30 PM ET

    Watch Transcript

  • Adaptive Biotechnologies (NASDAQ:ADPT) Q4 2025 Earnings Call

    Thu, Feb 05, 2026 · 7:30 PM ET

    Watch Transcript

Latest news

Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026

Oct 14, 2026

Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure

Sep 25, 2026

Adaptive Biotechnologies Announces Update to NCCN Guidelines for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ

Sep 18, 2026

Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Sep 1, 2026

Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)

Aug 4, 2026

Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results

Jul 29, 2026

Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026

Jul 9, 2026

Adaptive Biotechnologies: Imviva Biotech Receives FDA IDE Authorization for clonoSEQ® Assay in TENACITY-01 Clinical Trial

Jun 30, 2026

Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering

Jun 17, 2026

Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses

Jun 15, 2026

All Adaptive Biotechnologies Corporation news

Decks

Adaptive Biotechnologies Corporation on 6ix

News releases
27 in the last 12 months · 171 in all · newest Oct 14, 2026 · oldest 2019
Calls
24 calls with a replay · 24 with a transcript · latest Jul 29, 2026
Decks
32 decks · latest May 5, 2026

Where Adaptive Biotechnologies Corporation is listed

ListingExchangeCountryCurrency
NASDAQ:ADPT · Home listingNASDAQUnited StatesUSD
gettex:1HMgettexGermanyEUR
LS Exchange:A2PLR5LS ExchangeGermanyEUR
Lang & Schwarz:A2PLR5Lang & SchwarzGermanyEUR
Tradegate:1HMTradegateGermanyEUR
BOATS:ADPTBOATSUnited StatesUSD
Dusseldorf:1HM · This pageDusseldorfGermanyEUR
Frankfurt:1HMFrankfurtGermanyEUR
Hamburg:1HMHamburgGermanyEUR
Munich:1HMMunichGermanyEUR
Stuttgart:1HMStuttgartGermanyEUR

Log in to ask 6ix AI your own questions about Adaptive Biotechnologies Corporation.